BRAF and neoplasm: Administration of the BRAF small molecule inhibitor PLX4720 had similar effects in a murine model of melanoma; PLX4720 reduced tumor growth by promoting the formation of a more immune stimulatory microenvironment correlated with a reduced accumulation of CD11b+/GR-1+ myeloid cells (74).